AdaptVac plans to launch a trial of the Covid-19 vaccine before the end of this year. Credit: Bao_5 from Pixabay.

Bavarian Nordic has signed a final agreement with AdaptVac to licence a capsid virus-like particle (cVLP) based SARS-CoV-2 subunit vaccine.

Under the agreement, Bavarian Nordic will make an upfront payment of €4m to AdaptVac, which is also eligible for future development and sales milestones and royalties.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Excluding royalties, the agreement is valued at up to €136m.

The company signed an exclusive head of terms agreement for the Covid-19 vaccine in May this year. With the final agreement, Bavarian Nordic gains the global commercialisation rights to the potential vaccine.

AdaptVac CEO Wian de Jongh said: “This represents a big milestone for AdaptVac and our break-through cVLP technology. Bavarian Nordic joining the project significantly strengthens the Covid-19 cVLP vaccine development effort, and ensures the vaccine can reach the public as fast as possible.”

A member of the PREVENT-nCoV consortium, AdaptVac secured an EU Horizon grant earlier this year to advance its vaccine candidate into the clinic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company said that the vaccine technology’s manufacturing can be readily scaled to commercial quantities, partnering with AGC Biologics for the manufacture and scale-up of the vaccine.

Last month, preclinical data showed that the vaccine generated promising Covid-19 immunisation with a high level of SARS-CoV-2 virus neutralisation in a mice model.

Based on these findings, AdaptVac plans to launch a clinical trial of the vaccine before the end of this year, with results expected to be reported in the first quarter of next year.

Bavarian Nordic president and CEO Paul Chaplin said: “We are very pleased to have signed the agreement with AdaptVac, allowing us to support and rapidly advance this highly promising COVID-19 vaccine candidate.

“We continue to believe this vaccine candidate can address the WHO requirements to be safe and effective in all populations and induce rapid protection after a single vaccination.”

Bavarian Nordic will carry out further clinical development, manufacturing and commercialisation of the vaccine. The company will work towards obtaining regulatory approvals within the coming 12-18 months.